Desensitization of Myofilaments to Ca2+ as a Therapeutic Target for Hypertrophic Cardiomyopathy With Mutations in Thin Filament Proteins

Circulation: Cardiovascular Genetics

Volumn 7, Issue 2, 2014, Pages 132-143

  Alves, Marco L ^a,e   Dias, Fernando A L ^e   Gaffin, Robert D ^a   Simon, Jillian N ^a   Montminy, Eric M ^a   Biesiadecki, Brandon J ^a,d   Hinken, Aaron C ^a   Warren, Chad M ^a   Utter, Megan S ^a   Davis, Robert T ^a   Sadayappan, Sakthivel ^c   Robbins, Jeffrey ^c   Wieczorek, David F ^b   Solaro, R John ^a   Wolska, Beata M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Cardiac remodeling; Cardiomyopathies; Cardiomyopathy; Hypertrophic; Therapeutics

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ALPHA TROPOMYOSIN; CALCIUM ION; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLAMBAN; PROTEIN KINASE B; TRANSCRIPTION FACTOR GATA 4; TROPONIN I; TROPONIN T; CALCIUM; CALCIUM BINDING PROTEIN; TROPOMYOSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DIASTOLIC DYSFUNCTION; GENE MUTATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE PERFORMANCE; HISTOPATHOLOGY; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; MYOFILAMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE; ANIMAL; CARDIOMYOPATHY, HYPERTROPHIC; GENETICS; HUMAN; METABOLISM; MUSCLE FIBRIL; MUTATION; PHOSPHORYLATION;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CARDIOMYOPATHY, HYPERTROPHIC; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; MYOFIBRILS; PHOSPHORYLATION; TROPOMYOSIN; TROPONIN I; TROPONIN T;

EID: 84903591114     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000324     Document Type: Article

References (55)

1. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783-e831.
2. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816. (Pubitemid 43958474)
3. Hughes SE. The pathology of hypertrophic cardiomyopathy. Histopathology. 2004;44:412-427. (Pubitemid 38725670)
4. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881-1891. (Pubitemid 38748646)
5. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:201-211.
6. Brouwer WP, van Dijk SJ, Stienen GJ, van Rossum AC, van der Velden J, Germans T. The development of familial hypertrophic cardiomyopathy: from mutation to bedside. Eur J Clin Invest. 2011;41:568-578.
7. Ashrafian H, McKenna WJ, Watkins H. Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ Res. 2011;109:86-96.
8. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-276.
9. Tardiff JC. Thin filament mutations: developing an integrative approach to a complex disorder. Circ Res. 2011;108:765-782.
10. Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res. 2008;77:659-666. (Pubitemid 351301864)
11. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999-1006.
12. Marian AJ. Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J. 2009;36:194-204.
13. Nagueh SF, Lombardi R, Tan Y, Wang J, Willerson JT, Marian AJ. Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study. Eur J Clin Invest. 2010;40:976-983.
14. Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 2005;96:1563-1567. (Pubitemid 41690179)
15. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109:1284-1291. (Pubitemid 38372788)
16. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789-791. (Pubitemid 32163874)
17. Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol. 2006;47:827-834. (Pubitemid 43243108)
18. Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT, et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res. 2005;97:285-292. (Pubitemid 41105455)
19. Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, Chen J, et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation. 2009;119:1398-1407.
20. Gaffin RD, Peña JR, Alves MS, Dias FA, Chowdhury SA, Heinrich LS, et al. Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein. J Mol Cell Cardiol. 2011;51:812-820.
21. Peña JR, Szkudlarek AC, Warren CM, Heinrich LS, Gaffin RD, Jagatheesan G, et al. Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2010;49:993-1002.
22. Coutu P, Bennett CN, Favre EG, Day SM, Metzger JM. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ Res. 2004;94:1235-1241. (Pubitemid 38656410)
23. Zhang R, Zhao J, Mandveno A, Potter JD. Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res. 1995;76:1028-1035.
24. Wolska BM, Arteaga GM, Peña JR, Nowak G, Phillips RM, Sahai S, et al. Expression of slow skeletal troponin I in hearts of phospholamban knockout mice alters the relaxant effect of beta-adrenergic stimulation. Circ Res. 2002;90:882-888. (Pubitemid 34633880)
25. Pi Y, Kemnitz KR, Zhang D, Kranias EG, Walker JW. Phosphorylation of troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants expressed on a troponin I-null background in mice. Circ Res. 2002;90:649-656. (Pubitemid 34640882)
26. Peña JR, Wolska BM. Troponin I phosphorylation plays an important role in the relaxant effect of beta-adrenergic stimulation in mouse hearts. Cardiovasc Res. 2004;61:756-763. (Pubitemid 38249474)
27. Kentish JC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, et al. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res. 2001;88:1059-1065. (Pubitemid 34137119)
28. Sakthivel S, Finley NL, Rosevear PR, Lorenz JN, Gulick J, Kim S, et al. In vivo and in vitro analysis of cardiac troponin I phosphorylation. J Biol Chem. 2005;280:703-714. (Pubitemid 40165038)
29. Finley N, Abbott MB, Abusamhadneh E, Gaponenko V, Dong W, Gasmi- Seabrook G, et al. NMR analysis of cardiac troponin C-troponin I complexes: effects of phosphorylation. FEBS Lett. 1999;453:107-112. (Pubitemid 29337418)
30. Ward DG, Brewer SM, Gallon CE, Gao Y, Levine BA, Trayer IP. NMR and mutagenesis studies on the phosphorylation region of human cardiac troponin I. Biochemistry. 2004;43:5772-5781. (Pubitemid 38623611)
31. Dohet C, Al-Hillawi E, Trayer IP, Rüegg JC. Reconstitution of skinned cardiac fibres with human recombinant cardiac troponin-I mutants and troponin-C. FEBS Lett. 1995;377:131-134. (Pubitemid 26018520)
32. Prabhakar R, Boivin GP, Grupp IL, Hoit B, Arteaga G, Solaro RJ, et al. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J Mol Cell Cardiol. 2001;33:1815-1828. (Pubitemid 32977135)
33. Evans CC, Pena JR, Phillips RM, Muthuchamy M, Wieczorek DF, Solaro RJ, et al. Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2000;279:H2414-H2423.
34. Engel PL, Kobayashi T, Biesiadecki B, Davis J, Tikunova S, Wu S, et al. Identification of a region of troponin I important in signaling cross- bridge-dependent activation of cardiac myofilaments. J Biol Chem. 2007;282:183-193. (Pubitemid 47076645)
35. Dias FA, Walker LA, Arteaga GM, Walker JS, Vijayan K, Peña JR, et al. The effect of myosin regulatory light chain phosphorylation on the frequency- dependent regulation of cardiac function. J Mol Cell Cardiol. 2006;41:330-339. (Pubitemid 44080223)
36. Warren CM, Arteaga GM, Rajan S, Ahmed RP, Wieczorek DF, Solaro RJ. Use of 2-D DIGE analysis reveals altered phosphorylation in a tropomyosin mutant (Glu54Lys) linked to dilated cardiomyopathy. Proteomics. 2008;8:100-105.
37. Gaffin RD, Chowdhury SA, Alves MS, Dias FA, Ribeiro CT, Fogaca RT, et al. Effects of nicotine administration in a mouse model of familial hypertrophic cardiomyopathy, α-tropomyosin D175N. Am J Physiol Heart Circ Physiol. 2011;301:H1646-H1655.
38. Layland J, Cave AC, Warren C, Grieve DJ, Sparks E, Kentish JC, et al. Protection against endotoxemia-induced contractile dysfunction in mice with cardiac-specific expression of slow skeletal troponin I. FASEB J. 2005;19:1137-1139. (Pubitemid 40946443)
39. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. 2012;110:841-850.
40. Alves ML, Gaffin RD, Wolska BM. Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. J Mol Cell Cardiol. 2010;48:834-842.
41. Willott RH, Gomes AV, Chang AN, Parvatiyar MS, Pinto JR, Potter JD. Mutations in Troponin that cause HCM, DCM AND RCM: what can we learn about thin filament function? J Mol Cell Cardiol. 2010;48:882-892.
42. Jagatheesan G, Rajan S, Petrashevskaya N, Schwartz A, Boivin G, Arteaga GM, et al. Rescue of tropomyosin-induced familial hypertrophic cardiomyopathy mice by transgenesis. Am J Physiol Heart Circ Physiol. 2007;293:H949-H958. (Pubitemid 47254193)
43. Li Y, Charles PY, Nan C, Pinto JR, Wang Y, Liang J, et al. Correcting diastolic dysfunction by Ca2+ desensitizing troponin in a transgenic mouse model of restrictive cardiomyopathy. J Mol Cell Cardiol. 2010;49:402-411.
44. Solaro RJ, Rarick HM. Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments. Circ Res. 1998;83:471-480. (Pubitemid 28411048)
45. Solaro RJ, Rosevear P, Kobayashi T. The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation. Biochem Biophys Res Commun. 2008;369:82-87.
46. Konhilas JP, Irving TC, Wolska BM, Jweied EE, Martin AF, Solaro RJ, et al. Troponin I in the murine myocardium: influence on length-dependent activation and interfilament spacing. J Physiol. 2003;547(Pt 3):951-961. (Pubitemid 36367375)
47. Strang KT, Sweitzer NK, Greaser ML, Moss RL. Beta-adrenergic receptor stimulation increases unloaded shortening velocity of skinned single ventricular myocytes from rats. Circ Res. 1994;74:542-549.
48. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001;276:9337-9343.
49. van der Velden J, Papp Z, Zaremba R, Boontje NM, de Jong JW, Owen VJ, et al. Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res. 2003;57:37-47. (Pubitemid 36009434)
50. Frey N, Luedde M, Katus HA. Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol. 2012;9:91-100.
51. Fentzke RC, Buck SH, Patel JR, Lin H, Wolska BM, Stojanovic MO, et al. Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart. J Physiol. 1999;517 (Pt 1):143-157. (Pubitemid 29243478)
52. Muthuchamy M, Pieples K, Rethinasamy P, Hoit B, Grupp IL, Boivin GP, et al. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Circ Res. 1999;85:47-56. (Pubitemid 29321041)
53. Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res. 2010;61:269-280.
54. Kehat I, Davis J, Tiburcy M, Accornero F, Saba-El-Leil MK, Maillet M, et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res. 2011;108:176-183.
55. Baudenbacher F, Schober T, Pinto JR, Sidorov VY, Hilliard F, Solaro RJ, et al. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest. 2008;118:3893-3903.